RET and medullary thyroid gland carcinoma: Building on the knowledge that germline or somatic mutations of RET account for 75% of MTC, a randomized, double-blind phase 3 trial involving 331 patients was conducted utilizing vandetanib an oral inhibitor of RET, VEGFR, and EGFR.